Glenmede Trust’s Vanda Pharmaceuticals VNDA Stock Holding History

Glenmede Trust’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,484	Closed	-$13K	–	2234
2020 Q3	$13K	Hold	1,484	–	–	﹤0.01%	1791
2020 Q2	$16K	Buy	1,484 +248	+20%	+$2.81K	﹤0.01%	1686
2020 Q1	$20K	Hold	1,236	–	–	﹤0.01%	2106
2019 Q4	$20K	Buy	1,236 +169	+16%	+$2.56K	﹤0.01%	2106
2019 Q3	$13	Sell	1,067 -425,659	-100%	-$5.93M	﹤0.01%	2252
2019 Q2	$6.01K	Sell	426,726 -1,381,475	-76%	-$22M	0.03%	437
2019 Q1	$33.3K	Buy	1,808,201 +534,990	+42%	+$12.2M	0.15%	210
2018 Q4	$33.3K	Sell	1,273,211 -493,535	-28%	-$11.6M	0.16%	179
2018 Q3	$40.5M	Buy	1,766,746 +1,766,208	+328,291%	+$36.1M	0.16%	200
2018 Q2	$10K	Sell	538 -36	-6%	-$602	﹤0.01%	1909
2018 Q1	$8K	Hold	574	–	–	﹤0.01%	2265
2017 Q4	$8K	Buy	+574	New	+$8.52K	﹤0.01%	2265

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Glenmede Trust's VNDA Position: Q4 2020 in Review

Glenmede Trust sold out of Vanda Pharmaceuticals (VNDA) in Q4 2020, closing a stake of 1,484 shares — an estimated $13K sold.

Glenmede Trust first reported a position in VNDA in Q4 2017 and held it in 12 quarters. The position peaked at $40.5M in Q3 2018. 178 funds tracked by Wall St. Rank hold VNDA as of Q4 2020.

Glenmede Trust reported no remaining Vanda Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 1,484 Vanda Pharmaceuticals shares in Q4 2020, an estimated $13K.
Glenmede Trust first reported a position in Vanda Pharmaceuticals in Q4 2017 and held it in 12 quarters.
Glenmede Trust's Vanda Pharmaceuticals position peaked at $40.5M in Q3 2018.
178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.